Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.46 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13340824 | 0.84 | GABRG2 (0.40) | PDE3BPDE3ASLC9A1LMNANR1H3 | |
| SCHEMBL13340980 | 0.84 | SLC9A1 (0.57) | PDE3BPDE3ASLC9A1NR1H3OPRM1 | |
| SCHEMBL13340925 | 0.82 | OPRD1 (0.43) | PDE3BPDE3ASLC9A1OPRK1NR3C2 | |
| SCHEMBL13340990 | 0.82 | SLC9A1 (0.37) | PDE3BPDE3ASLC9A1NR1H3OPRM1 | |
| SCHEMBL13340916 | 0.81 | SLC9A1 (0.39) | SLC9A1OPRK1NR3C2POLBKMT2A | |
| SCHEMBL13340970 | 0.80 | NR3C2 (0.42) | PDE3BPDE3ALMNANR1H3OPRM1 | |
| SCHEMBL15161226 | 0.80 | PDE3B (0.49) | PDE3BPDE3ASLC9A1LMNAKRAS | |
| SCHEMBL13340926 | 0.79 | SLC9A1 (0.35) | SLC9A1LMNANR1H3OPRM1OPRK1 | |
| SCHEMBL13340988 | 0.79 | CRHR1 (0.36) | PDE3BPDE3ASLC9A1OPRM1OPRK1 | |
| SCHEMBL16362034 | 0.78 | PDE3B (0.51) | PDE3BPDE3ASLC9A1LMNANR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8318755-B2 | Inhibitors of SYK and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120130073-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130073-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | PDE3B 1361/4885PDE3A 1592/4885SLC9A1 3984/4885 |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | PDE3B 113/4885PDE3A 138/4885SLC9A1 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.